BRIEF-Pfizer Says In Overall Study Population Through Day 28, No Deaths Were Reported In Patients Who Received Co's Covid-19 Oral Antiviral Candidate
Nov 5 (Reuters) - PFIZER:
* PFIZER´S EXPERIMENTAL COVID-19 ORAL ANTIVIRAL TREATMENT CUT RISK OF HOSPITALIZATION OR DEATH BY 89% IN INTERIM ANALYSIS OF PHASE 2/3 STUDY
* PFIZER - AT RECOMMENDATION OF INDEPENDENT SAFETY BOARD, WILL CEASE FURTHER STUDY ENROLLMENT DUE TO OVERWHELMING EFFICACY FROM INTERIM RESULTS
* PFIZER - PLANS TO SUBMIT DATA FROM INTERIM ANALYSIS OF STUDY AS PART OF ONGOING ROLLING SUMISSION TO FDA FOR EUA AS SOON AS POSSIBLE
* PFIZER - IN OVERALL STUDY POPULATION THROUGH DAY 28, NO DEATHS WERE REPORTED IN PATIENTS WHO RECEIVED CO'S COVID-19 ORAL ANTIVIRAL CANDIDATE Source text for Eikon: Further company coverage:
